Twelve months ago, Humana’s Medicare Advantage star ratings were a liability. On Friday, they became the reason one of Wall Street’s biggest managed-care desks pulled off the sidelines on the stock.
Barclays upgraded Humana from Equal Weight to Overweight, simultaneously raising its price target from $407 to $515, and the market treated the move as significant. The stock climbed as much as about 9% intraday. UNH gained just 0.7% while XLV stayed flat, supporting the idea the rally is Humana-specific rather than a broad managed-care reappraisal. The jump leaves Humana shares up about 60% year to date.
The Thesis in One Contract
Barclays analyst Andrew Mok upgraded the stock ahead of the October star ratings catalyst, expected around Oct. 8, based on an increasingly constructive view that Humana will flip several contracts to bonus status, including H5216, which is Humana’s largest Medicare Advantage contract and has been reported by industry analysts as having more than 2.7 million members. The H5216 contract represents a critical component of the company’s long-term 2028 EPS target and is worth approximately $1.5 billion of EBIT and $9 of EPS.
Mok raised the probability that Humana’s H5216 contract will be upgraded to 75%. That is a specific number attached to a specific claim, not a vague endorsement of management’s turnaround story, and it explains why the upgrade moved shares more than a routine target raise would.
What CMS Is Actually Grading On
The October 8 release is not a formality. A single half-star swing can move hundreds of millions of dollars in bonus payments for a large insurance contract. Contracts reaching four stars qualify for higher federal bonus payments, and higher scores also produce larger rebates when plans bid below the CMS benchmark.
The grading sheet itself got harder. About 50% of cutpoints got harder, 33% were unchanged, and 17% actually got easier, according to analysis by the Newton Smith Group, an MA consultancy. About half of cutpoints got harder, mostly in HEDIS measures, which span more than 90 measures across six domains used to rate plan quality and performance. Many HEDIS thresholds are rising as plans invest more in data collection, making it harder for insurers without good data capabilities to keep up.
This is the structural tension Barclays is betting Humana has resolved. Humana’s Medicare Advantage plans rated 4-star or higher declined sharply for 2025, and Humana sued CMS seeking to set aside those 2025 star ratings. For 2026, Humana reported that about 20% of its members were in plans with at least 4 stars, down from 25% the prior year. Bouncing back from those losses is what the 2027 ratings need to demonstrate.
The Bull and Bear Cases
Management has been executing margin restoration while expanding CenterWell primary care services. Humana has also reported insider buying within the past 12 months, but public filings and third-party trackers do show some insider sales in that same window, so the cleaner takeaway is simply that there has been at least some insider buying. Those are supporting details, not the main event. The main event is whether Humana’s operational improvements since 2025 are enough to clear a bar that just got higher for half its measures.
The bear case is straightforward. Draft cutpoints are not final and CMS has adjusted before. Analysts have suggested some large insurers could see contracts slip below four stars, and further litigation is possible. If H5216 does not flip to bonus status, the $515 target loses its foundation.
What to Watch
Medicare open enrollment starts October 15, one week after ratings are expected to drop, and runs through December 7. Bonus status affects what benefits Humana can afford to offer members, which flows directly into enrollment trends for 2027. Plans that cannot clear the four-star bonus line can wind up with less room to fund the richer benefits Medicare Advantage is known for. Competitors UNH, CVS’s Aetna, ELV, and CI face the same grading system, so the October 8 release will re-rank the entire sector in a single morning.
Barclays has named its number and assigned a 75% probability to the outcome that justifies it. Investors have less than two weeks to decide whether that conviction is worth paying for at $403.
